Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 5;79(4):1088–1098. doi: 10.1093/cid/ciae365

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Non-inferiority of FLU-aQIV and RSVPreF3 OA co-administration versus sequential administration, evaluated by adjusted GMT ratios for influenza HI and RSV neutralizing titers A, as well as influenza MN titers for A/Darwin (H3N2) B, (per-protocol sets for flu and RSV analyses). CIs are depicted as error bars. Success criterion for non-inferiority: upper limits of 2-sided 95% CIs for adjusted geometric mean titer (GMT) ratios (Control/Co-Ad) for each FLU-aQIV strain and for RSV-A and RSV-B were ≤1.50 at 1 m post-vaccination. Abbreviations: CI, confidence interval; FLU-aQIV, adjuvanted inactivated seasonal quadrivalent influenza vaccine; HI, hemagglutination inhibition; MN, microneutralization; RSVPreF3 OA, respiratory syncytial virus (RSV) prefusion F protein-based vaccine. ^aAs the non-inferiority analysis was performed sequentially, and the success criterion was not met for A/Darwin (H3N2), non-inferiority for RSV-B neutralization titers was no longer a confirmatory endpoint and was evaluated descriptively.